Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
20.73 AUD | -1.33% | +2.62% | -16.98% |
May. 09 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.98% | 1.79B | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- US FDA Accepts Neuren Pharmaceuticals' Licensed Drug for Use in Rhett Syndrome; Shares Rise 4%